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Molecular genetic testing has not been used extensively as the primary diagnostic test for LSDs 
but this may change with the advent of rapid, reliable and affordable high-throughput DNA 
sequencing, the so called next generation sequencing.  
The aim of this work was to develop a next-generation sequencing (NGS)-based workflow for 
the identification of variations in exons and their intronic flanking regions in genes involved in 
lysosomal function. Our NGS-based workflow was designed using an Agilent SureSelect Target 
Enrichment protocol followed by sequencing by an Illumina MiSeq platform. The complete 
gene list includes 96 genes encoding for lysosomal proteins, lysosomal regulators and non-
lysosomal proteins involved in lysosomal biogenesis. All genes encoding non-lysosomal 
proteins may play a role in lysosomal function and in LSDs.  
As proof of sensitivity and specificity, a set of 12 samples from patients affected by several 
types of LSDs was tested. We analyzed samples from Mucolipidosis II alpha/beta, 
Mucopolysaccharidosis type VI, Gaucher Disease, Fabry disease, Pycnodysostosis, Krabbe 
disease, GM2-gangliosidosis, and Neuronal Ceroid Lipofuscinosis. In 5 of them causative 
mutations had been previously identified, while in 4 only the pathology was known and in the 
remaining 3, even the specific disease was unknown. Using our protocol we were able to 
detect all the known mutations and characterize the mutations in the patients where the 
pathology was identified. Currently, we are still analyzing the unknown cases to identify the 
putative pathogenic variations. 
This gene panel seems therefore to be a valid tool for the genetic analysis of lysosomal gene 
mutations. In addition, it provides a comprehensive view on the role that variants in 96 genes 
involved in the lysosomal function plays in health and disease.  
